Patents by Inventor Weng K. Chang
Weng K. Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250002471Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.Type: ApplicationFiled: December 21, 2021Publication date: January 2, 2025Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Scott E. Lazerwith, Daniel G. Shore
-
Patent number: 12091420Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.Type: GrantFiled: October 3, 2023Date of Patent: September 17, 2024Assignee: Gilead Sciences, Inc.Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Jessica L. Mckinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
-
Patent number: 12070455Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.Type: GrantFiled: September 8, 2022Date of Patent: August 27, 2024Assignee: Gilead Sciences, Inc.Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore
-
Publication number: 20240239807Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.Type: ApplicationFiled: August 4, 2023Publication date: July 18, 2024Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
-
Publication number: 20240217990Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.Type: ApplicationFiled: February 8, 2022Publication date: July 4, 2024Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Julian A. Codelli, Lan Jiang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Scott D. Schroeder, Daniel G. Shore
-
Patent number: 11976083Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.Type: GrantFiled: April 28, 2021Date of Patent: May 7, 2024Assignee: Gilead Sciences, Inc.Inventors: Eda Y. Canales, Weng K. Chang, Laurent P. Debien, Petr Jansa, Jennifer A. Loyer-Drew, Luisruben P. Martinez, Stephane Perreault, Gary B Phillips, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen
-
Publication number: 20240116946Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.Type: ApplicationFiled: October 3, 2023Publication date: April 11, 2024Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
-
Publication number: 20240059673Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.Type: ApplicationFiled: December 21, 2021Publication date: February 22, 2024Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Scott E. Lazerwith, Daniel G. Shore
-
Publication number: 20230365594Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.Type: ApplicationFiled: March 8, 2023Publication date: November 16, 2023Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore, Christopher J. Swank
-
Publication number: 20230270734Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.Type: ApplicationFiled: September 8, 2022Publication date: August 31, 2023Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore
-
Patent number: 11661431Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.Type: GrantFiled: April 15, 2022Date of Patent: May 30, 2023Assignee: Gilead Sciences, Inc.Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore, Christopher J. Swank
-
Publication number: 20230002412Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.Type: ApplicationFiled: April 28, 2021Publication date: January 5, 2023Inventors: Eda Y. Canales, Weng K. Chang, Laurent P. Debien, Petr Jansa, Jennifer A. Loyer-Drew, Luisruben P. Martinez, Stephane Perreault, Gary B. Phillips, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen
-
Publication number: 20220389034Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.Type: ApplicationFiled: April 15, 2022Publication date: December 8, 2022Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore, Christopher J. Swank
